✦ LIBER ✦

Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study

✍ Scribed by Angeles Alvarez Secord; John A. Blessing; Deborah K. Armstrong; William H. Rodgers; Zoe Miner; Mack N. Barnes; George Lewandowski; Robert S. Mannel

Book ID: 113961446
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 571 KB
Volume: 108
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2007.11.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II Trial of Pyrazoloacridine in Re

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

✍ Steven C. Plaxe; John A. Blessing; Michael A. Bookman; William T. Creasman 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Phase II study of cisplatin plus cetuxim

Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study

✍ John Farley; Michael W. Sill; Michael Birrer; Joan Walker; Russell J. Schilder; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 309 KB

Phase II Evaluation of 24-h Continuous I

Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

✍ Maurie Markman; John A. Blessing; Ronald D. Alvarez; Parviz Hanjani; Steven Wagg 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Phase II evaluation of three-day topotec

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a

A phase II evaluation of bortezomib in t

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

✍ Carol Aghajanian; John A. Blessing; Kathleen M. Darcy; Gary Reid; Koen DeGeest; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 589 KB

Evaluation of Cisplatin and Cyclosporin

Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

✍ Alberto Manetta; John A. Blessing; Jean A. Hurteau 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 29 KB